Elite Pharmaceuticals ( (ELTP) ) has shared an update.
Elite Pharmaceuticals, Inc. reported a robust financial performance for the second quarter of fiscal year 2025, with a 33% rise in revenues to $18.9 million and an 84% increase in operating profits to $3.5 million, driven by strong sales of its generic product line. The company will discuss these results and recent business developments in an upcoming conference call.
See more insights into ELTP stock on TipRanks’ Stock Analysis page.
